Literature DB >> 24074877

Dimeric argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 and Y4 receptors.

Max Keller1, Melanie Kaske, Tobias Holzammer, Günther Bernhardt, Armin Buschauer.   

Abstract

The structurally related peptides neuropeptide Y (NPY), peptide YY (PYY) and pancreatic polypeptide (PP) are endogenous agonists of the NPY receptor (YR) family, which in humans comprises four functionally expressed subtypes, designated Y1R, Y2R, Y4R and Y5R. Nonpeptide antagonists with high affinity and selectivity have been described for the Y1R, Y2R and Y5R, but such compounds are still lacking for the Y4R. In this work, the structures of the high affinity selective (R)-argininamide-type Y1R antagonists BIBP3226 and BIBO3304 were linked via the guanidine or urea moieties to give homo-dimeric argininamides with linker lengths ranging from 31 to 41 atoms. Interestingly, the twin compounds proved to be by far less selective for the Y1R than the R-configured monovalent parent compounds. The decrease in selectivity ratio was most pronounced for Y1R versus Y4R subtype, resulting in comparable affinities of bivalent ligands for Y1R and Y4R (e.g. UR-MK177 ((R,R)-49): Ki=230nM (Y1R) and 290nM (Y4R)). With a Ki value of 130nM and a Kb value of 20nM, UR-MK188 ((R,R)-51) was superior to all Y4R antagonists known to date. The S,S-configured optical antipodes of UR-MK177 and UR-MK188 (UR-MEK381 ((S,S)-49) and UR-MEK388 ((S,S)-51)) were synthesized to investigate the stereochemical discrimination by the different receptor subtypes. Whereas preference for R,R-configured argininamides was characteristic of the Y1R, stereochemical discrimination by the Y4R was not observed. This may pave the way to selective Y4R antagonists.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bivalent ligand; Dimeric argininamide derivatives; NPY Y(1) receptor antagonist; Neuropeptide Y; Y(4) receptor antagonist

Mesh:

Substances:

Year:  2013        PMID: 24074877     DOI: 10.1016/j.bmc.2013.08.065

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Prototypic 18F-Labeled Argininamide-Type Neuropeptide Y Y1R Antagonists as Tracers for PET Imaging of Mammary Carcinoma.

Authors:  Max Keller; Simone Maschauer; Albert Brennauer; Philipp Tripal; Norman Koglin; Ralf Dittrich; Günther Bernhardt; Torsten Kuwert; Hans-Jürgen Wester; Armin Buschauer; Olaf Prante
Journal:  ACS Med Chem Lett       Date:  2017-02-21       Impact factor: 4.345

2.  In Search of NPY Y4R Antagonists: Incorporation of Carbamoylated Arginine, Aza-Amino Acids, or d-Amino Acids into Oligopeptides Derived from the C-Termini of the Endogenous Agonists.

Authors:  Kilian K Kuhn; Timo Littmann; Stefanie Dukorn; Miho Tanaka; Max Keller; Takeaki Ozawa; Günther Bernhardt; Armin Buschauer
Journal:  ACS Omega       Date:  2017-07-14

3.  Heterodimerization of Dibenzodiazepinone-Type Muscarinic Acetylcholine Receptor Ligands Leads to Increased M2R Affinity and Selectivity.

Authors:  Xueke She; Andrea Pegoli; Judith Mayr; Harald Hübner; Günther Bernhardt; Peter Gmeiner; Max Keller
Journal:  ACS Omega       Date:  2017-10-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.